TVT STS / ACC registrywas developed to obtain data from all patients undergoing percutaneous aortic valve replacement (TAVR) in the United States. The clinical outcome at 30 days was recently published (Macket al, JAMA 2013) but there are few data on the longer-term treatment that is already incorporated in clinical practice in the United States.The registry included 5980 patients from 230 centers between November 2011 and June 2013.The average age of the population was 85 years with a mean STS score of 7.1 % (< 8% = 57 %, 8-15% = 30.8 % and > 15% = 12.2 %). The access was femoral in 63.7 % and 36.3 % in other.Year mortality was 26.2 % and the rate of stroke 3.6%. Predictors of death were age, male gender, degree in chronic obstructive pulmonary disease, renal failure and type of vascular access.The incidence of stroke was significantly higher in women (4.3 % versus 2.9 %, P = 0.012).
Conclusion
The TVT registry has data from virtually all patients undergoing TAVR in the United States with the Edwards prosthesis. The evolution observed at one year in the American experience is similar to other records.
David R. Holmes
2014-03-31
Title: One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
